Technical Analysis for MPH - Mereo Biopharma Group Limited

Grade Last Price % Change Price Change
F 26.5 -1.85% -0.50
MPH closed down 1.85 percent on Thursday, December 17, 2020, on 48 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical MPH trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Hammer Candlestick Bullish -1.85%
Lizard Bullish Bullish Day Trade Setup -1.85%
Older End-of-Day Signals for MPH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Mereo Biopharma Group Limited Description

Mereo BioPharma Group plc is a United Kingdom-based specialty biopharmaceutical company. The Company is engaged in the research and development of pharmaceuticals. It operates through three segments: Respiratory Unit, Endocrinology Disorders Unit and Orphan Diseases Unit. The Respiratory Unit segment develops drugs to treat respiratory diseases. The Endocrinology Disorders Unit segment develops drugs to treat endocrine disorders. The Orphan Diseases Unit segment develops drugs to treat various orphan diseases. It is engaged in the Phase II dose-ranging study with its oral anti-inflammatory agent, BCT-197, for treatment of the underlying inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Its product candidate, BPS-804, is in Phase II b/III study in patients with osteogenesis imperfecta (OI). It has initiated a Phase II b study with its oral aromatase inhibitor BGS-649 for the treatment of hypogonadal hypogonadism (HH) in obese men.


Sector: Healthcare
Industry: Biotechnology
Keywords: Chemistry Pharmaceutical Physical Sciences Pharmaceuticals Bp Disease Diseases Drugs Pharmaceutical Industry Biopharmaceutical Respirator Health Sciences Disorders Medication Respiratory Disease Chronic Obstructive Pulmonary Disease Respiratory Diseases Inflammation Copd Hypogonadism Organofluorides Orphan Diseases

Is MPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 60.0
52 Week Low 13.0
Average Volume 103,172
200-Day Moving Average 34.51
50-Day Moving Average 33.59
20-Day Moving Average 31.50
10-Day Moving Average 29.60
Average True Range 2.10
ADX 34.4
+DI 8.71
-DI 32.81
Chandelier Exit (Long, 3 ATRs ) 29.39
Chandelier Exit (Short, 3 ATRs ) 31.31
Upper Bollinger Band 36.72
Lower Bollinger Band 26.28
Percent B (%b) 0.02
BandWidth 33.17
MACD Line -2.00
MACD Signal Line -1.47
MACD Histogram -0.5285
Fundamentals Value
Market Cap 89.76 Million
Num Shares 339 Million
EPS -43.00
Price-to-Earnings (P/E) Ratio -0.62
Price-to-Sales 0.00
Price-to-Book 4.61
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.25
Resistance 3 (R3) 27.17 26.83 27.13
Resistance 2 (R2) 26.83 26.64 26.88 27.08
Resistance 1 (R1) 26.67 26.52 26.75 26.75 27.04
Pivot Point 26.33 26.33 26.38 26.38 26.33
Support 1 (S1) 26.17 26.14 26.25 26.25 25.96
Support 2 (S2) 25.83 26.02 25.88 25.92
Support 3 (S3) 25.67 25.83 25.88
Support 4 (S4) 25.75